LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

Mayo Clinic logo

Mayo Clinic

Status and phase

Completed
Phase 2

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Treatments

Drug: Budesonide
Drug: Formoterol
Drug: Placebo

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT01783821
12-008192
UL1RR024150 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD), but the use of these two drugs is experimental for ARDS.

Full description

Subjects were randomized to either placebo or combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 calendar days for a total of 10 doses or until hospital discharge or death. Local hospital pharmacies prepared identical appearing solutions and drug was delivered by respiratory therapists blinded to randomization by using standard jet nebulizers that produce aerosol particle size within the respirable range (<5.5 microns). The first dose was administered within 4 hours after randomization.

Enrollment

61 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients (age > 18)
  • Admitted to the hospital through the emergency department (ED)
  • High risk of developing ARDS (Lung Injury Prediction Score (LIPS) greater than or equal to four)

Exclusion criteria

  • Inhaled corticosteroid and/or beta agonist treatment on admission or within 7 days prior to admission (history of asthma or COPD necessitating therapy)
  • Chronic pulmonary disease requiring daytime oxygen supplementation therapy
  • Systemic steroid treatment on admission or within 7 days prior to admission equivalent to more than 5 mg of prednisone daily
  • Inability to obtain consent within 12 hours of hospital presentation
  • Acute lung injury prior to randomization
  • Receiving mechanical ventilation before current hospital admission (patient who is ventilator dependent)
  • Presentation believed to be purely due to heart failure without other known risk factors for ARDS
  • Allergy or other contraindication to either budesonide and/or formoterol use
  • Expected hospital stay and/or survival <48 hours or admission for comfort or hospice care
  • Patient, surrogate or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
  • Previous enrollment in this trial.
  • Co-enrollment with LIPS-A trial is not allowed.
  • An active enrollment in other concomitant trial will be judged on case by case basis by PIs of both trials.
  • EKG and/or clinical presentation suggestive of acute coronary ischemia
  • New onset cardiac arrhythmia
  • Current atrial fibrillation with ventricular rate of >110/minute
  • Persistent sinus tachycardia of >130/minute despite early goal directed therapy with fluids, pressors, antibiotics and supplemental oxygen
  • Pregnant patients

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

61 participants in 2 patient groups, including a placebo group

Budesonide and Formoterol
Experimental group
Description:
Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
Treatment:
Drug: Formoterol
Drug: Budesonide
Placebo
Placebo Comparator group
Description:
Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
Treatment:
Drug: Placebo

Trial contacts and locations

5

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems